Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Prometheus Biosciences stock
Learn how to easily invest in Prometheus Biosciences stock.
Prometheus Biosciences is a biotechnology business based in the US. Prometheus Biosciences shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences employs 72 staff and has a trailing 12-month revenue of around $7.2 million.
How to buy Prometheus Biosciences stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – RXDX. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Trade stocks and ETFs for $0 and no annual fee
- Minimum deposit of $10 required
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Prometheus Biosciences stock price (NASDAQ: RXDX)Use our graph to track the performance of RXDX stocks over time.
Prometheus Biosciences shares at a glance
|Latest market close||$113.66|
|52-week range||$21.50 - $122.75|
|50-day moving average||$86.85|
|200-day moving average||$51.80|
|Wall St. target price||$146.18|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.78|
Buy Prometheus Biosciences stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Prometheus Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Prometheus Biosciences price performance over time
|1 week (2023-01-25)||-4.58%|
|1 month (2022-12-30)||3.33%|
|3 months (2022-11-02)||122.43%|
|6 months (2022-08-02)||172.11%|
|1 year (2022-02-02)||216.43%|
|2 years (2021-01-29)||N/A|
|3 years (2020-01-29)||N/A|
|5 years (2018-01-29)||N/A|
Prometheus Biosciences financials
|Revenue TTM||$7.2 million|
|Gross profit TTM||$-59,298,000|
|Return on assets TTM||-27.21%|
|Return on equity TTM||-53.74%|
|Market capitalisation||$5.5 billion|
TTM: trailing 12 months
Prometheus Biosciences share dividends
We're not expecting Prometheus Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
- Vedanta (VEDL.US) (9.05% forward annual dividend yield)
Have Prometheus Biosciences's shares ever split?
Prometheus Biosciences's shares were split on a 1:100 basis on 31 October 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Prometheus Biosciences shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Prometheus Biosciences shares which in turn could have impacted Prometheus Biosciences's share price.
Prometheus Biosciences overview
Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc.
Prometheus Biosciences in the news
Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB
Biotech's Blockbuster Week: 3 Stocks to Watch
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Frequently asked questionsWhat percentage of Prometheus Biosciences is owned by insiders or institutions?
Currently 19.172% of Prometheus Biosciences shares are held by insiders and 73.341% by institutions. How many people work for Prometheus Biosciences?
Latest data suggests 72 work at Prometheus Biosciences. When does the fiscal year end for Prometheus Biosciences?
Prometheus Biosciences's fiscal year ends in December. Where is Prometheus Biosciences based?
Prometheus Biosciences's address is: 9410 Carroll Park Drive, San Diego, CA, United States, 92121 What is Prometheus Biosciences's ISIN number?
Prometheus Biosciences's international securities identification number is: US74349U1088
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert